Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 71

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 71
---
 the period commencing July 24, 2024 through December 31, 2024 (Successor and Predecessor) to the period commencing July 24, 2024 through December 31, 2024 (Predecessor)

The following table is data derived from the
Consolidated Statement of Operations (in thousands) and the discussions that follow are in approximate amounts.

|                                     |     | Successor and Predecessor |       |   |     |         Predecessor |     |
|                                     |     |                   For the 
                    period 
        commencing July 24 |       |   |     |             For the 
              period 
  commencing July 24 |     |
|                                     |     |       through December 31 |       |   |     | through December 31 |     |
|                                     |     |                      2024 |       |   |     |                2024 |     |
|                                     |     |                 Unaudited |       |   |     |           Unaudited |     |
| Operating expenses                  |     |                           |       |   |     |                     |     |
| Research and development expenses   |     |                           |   996 |   |     |                     | 670 |
| General and administrative expenses |     |                           | 1,153 |   |     |                     | 103 |
| Operating loss                      |     |                           | 2,149 |   |     |                     | 773 |
| Financial expense (income), net     |     |                           |   (65 | ) |     |                     |  10 |
| Net loss and comprehensive loss     |     |                           | 2,084 |   |     |                     | 783 |

Research and Development Expenses

Successor’s and Predecessor’s research
and development expenses totaled $996 thousand for the period commencing July 24, 2024 through December 31, 2024, representing an increase
of $326 thousand, or 48.6%, compared to Predecessor’s $670 thousand for the same period. The research and development expenses
comprise mainly from salaries and related expenses, from share based payment expenses and other expenses. The increase was due to share
based payment expense recorded in the fourth quarter of 2024 following options grant occurred in December 2024 .

General and Administrative Expenses

Successor’s and Predecessor’s general
and administrative expenses totaled $1,153 thousand for the period